Exciting Financing for AusperBio's Groundbreaking Work
AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. formed a key partnership dedicated to delivering targeted therapies for chronic hepatitis B (CHB). Their successful Series B financing, amounting to $73 million, paves the way for significant advancements in their clinical research.
Details of the Series B Financing Round
The fundraising was spearheaded by HanKang Capital, with notable participation from Sherpa Capital, CDH Investments, and several existing investors. This robust financial backing follows an earlier Series A round, indicating unwavering confidence in AusperBio's innovative platform.
Use of Funds to Drive Development
The funds will be utilized to further the Phase 2 development of AusperBio's lead therapy, AHB-137. This compound is set for extensive clinical trials, not only in China but also globally, alongside efforts to scale manufacturing capabilities.
Remarks from Leadership
Dr. Guofeng Cheng, co-founder and CEO of AusperBio, expressed gratitude, stating, "Investor confidence in our clinical advancements is tremendous, and this funding helps us work towards a functional cure for those battling CHB." His optimism is shared by Dr. Chris Yang, the company’s co-founder and CSO, who noted that recent presentations have bolstered interest in their innovative therapeutic approach.
Overview of AHB-137
AHB-137 is an advanced antisense oligonucleotide therapy designed to target chronic hepatitis B effectively. It has been through rigorous preclinical studies and Phase 1 trials, earning recognition at major medical conferences. Its development strategy uniquely positions AHB-137 to accelerate toward delivering potent cures for HBV.
About AusperBio
AusperBio operates as a clinical-stage biopharmaceutical firm focused on oligonucleotide therapies and targeted drug delivery systems. With a dedicated mission to transform chronic hepatitis B treatment, the company's Med-Oligo™ ASO platform integrates cutting-edge design insights to vastly improve therapeutic outcomes.
Innovative Therapeutic Focus
The Med-Oligo™ platform represents a substantial leap forward for ASO therapeutics, demonstrating effectiveness across a range of conditions, such as viral infections and genetic disorders. AusperBio's commitment underscores a transformative approach in modern biopharmaceuticals.
Frequently Asked Questions
What is AusperBio's main focus?
AusperBio is dedicated to advancing therapies specifically targeting chronic hepatitis B, aiming to provide a functional cure.
Who led the Series B financing for AusperBio?
HanKang Capital led the recent $73 million Series B financing, showcasing strong investor interest.
What is AHB-137?
AHB-137 is AusperBio's lead therapy designed to achieve a functional cure for chronic hepatitis B through innovative antisense oligonucleotide technology.
What is the Med-Oligo™ ASO platform?
The Med-Oligo™ ASO platform enhances antisense oligonucleotide therapies by providing advanced design features, improving effectiveness against various diseases.
What are the next steps for AusperBio?
The company plans to use the recent funding to propel the clinical trials of AHB-137 and expand its operational capabilities.
